FDA grants vaccine approval for moms-to-be to prevent RSV in newborns

The Food and Drug Administration has approved a vaccine for pregnant women to provide immediate protection against respiratory syncytial virus, or RSV, in infants. Abrysvo, is a single-dose vaccine produced by Pfizer and is approved for use between week 32 and week 36 of pregnancy. "This is especially exciting for us in pediatrics because vaccinating pregnant women in the second or third trimester of pregnancy can protect babies when they're most vulnerable for developing severe…
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news